Actively Recruiting
Phase II Study to Assess Safety and Effectiveness of HRS-9813 Capsules for Treating Pulmonary Fibrosis
Led by Guangdong Hengrui Pharmaceutical Co., Ltd · Updated on 2025-12-24
270
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of HRS-9813 in adults with pulmonary fibrosis, including idiopathic pulmonary fibrosis IPF and progressive pulmonary fibrosis PPF. This randomized, double-blind, placebo-controlled Phase II trial aims to understand how this investigational drug affects lung function and disease progression in these patients. Participants will be assigned randomly to one of three groups two groups receiving different doses of HRS-9813 capsules high dose and low dose and one group receiving a placebo capsule mimetic. The study treatment is given orally, and the primary treatment period lasts 26 weeks after administration. During the study, participants will undergo tests to measure lung function, including forced vital capacity FVC and lung carbon monoxide diffusion capacity DLCO. Researchers will also monitor hospitalizations related to pulmonary fibrosis, disease progression, acute exacerbations, and overall survival. Participants will be monitored for safety throughout the 26-week treatment period under close medical supervision.
CONDITIONS
Brief Title
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
Research Team
J
Jinrui Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here